AbbVie has terminated VIALE-T, its Phase 3 trial testing whether adding the BCL-2 inhibitor venetoclax (Venclexta) to azacitidine could extend life when given as maintenance to acute myeloid leukemia (AML) patients after an allogeneic stem-cell transplant. This post-transplant maintenance use is investigational and is not an approved indication. The registry lists the trial as terminated, with the sponsor’s stated reason being “Strategic considerations.” Separately, the registry has posted immature efficacy and safety results.
Relapse after transplant remains the central problem in AML, and a low-intensity maintenance regimen that could keep patients in remission has been a long-sought goal. VIALE-T enrolled 465 patients (start date February 26, 2020) and randomized them in Part 2 to venetoclax plus azacitidine with best supportive care (Arm A, n=214) or best supportive care alone (Arm B, n=216).
The Part 2 primary endpoint was overall survival. The point estimate did not favor the combination: the stratified hazard ratio was 1.2 (95% CI 0.81–1.77), numerically favoring supportive care, with a confidence interval that crosses 1.0. Importantly, the data are immature. Median survival was not evaluable in either arm, the pre-specified number of events was never reached, and formal hypothesis testing was not performed — so the estimate was not statistically tested and cannot be read as a definitive efficacy verdict.
The overall-survival point estimate numerically favored supportive care but was not statistically tested (95% CI 0.81–1.77); the sponsor cited “strategic considerations” for stopping.
Safety ran in the expected direction for an active regimen. In Part 2, serious adverse events occurred in 45% (97/214) of venetoclax-plus-azacitidine patients versus 31% (66/216) of supportive-care patients; 26% (56/214) of combination patients versus 21% (46/216) of supportive-care patients died during the adverse-event reporting period.
What the registry supports is narrow but clear: AbbVie stopped the trial for “strategic considerations,” and the posted overall-survival data show no signal favoring the combination at the point the study was halted — before its planned analysis. Venetoclax plus azacitidine remains a backbone in frontline AML; as investigational post-transplant maintenance, this early-terminated trial showed no survival signal favoring the combination in immature data before it was stopped, and was not powered or analyzed to deliver a definitive verdict.